Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
Clinical trial NCT03776136 · COMPLETED
Trial details
- NCT number
- NCT03776136
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-30
- Primary completion
- 2023-10-11
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.